Autism & I/DD

Intellectual and developmental disabilities (I/DD) are a physical and/or cognitive impairments that occur before the age of 22. Autism spectrum disorder is generally considered a type of developmental disability that affects behaviour and communication. The autism and I/DD market provides supports and health care services to these populations. Over the past decade, there has been an increase in the changes and challenges affecting I/DD and autism markets—the move to managed care and value-based care, the shift away from residential treatment, the increasing emphasis on consumer-directed care, and new workforce challenges.

Latest Resources

• Self-Direction Assessment Final Report
• Strategic Content Marketing As An Imperative For Brand & Referral Growth: The I Am Boundless Case Study
• I Am Boundless Expands Youth Services With Acquisition Of Multi-System Youth Homes
• Community Autism Services Opens New Center In Suwanee, Georgia
• New Medical Autism Clinic, ABA Intersect, Plans Opening In Sugar Land, Texas In October 2025
• Arizona Pauses Newly Updated Needs Assessment For Children With Developmental Disabilities
• 21 & Change Concludes Operations
• Arizona Long-Term Care System Emergency Rule & Policy For Minor Children: Frequently Asked Questions
• Florida Medicaid MCO For People With I/DD Reports Enrollment Growth
• Arizona DDD Begins Using A New Developmental Disability Assessment For Children To Determine Eligibility For Medicaid Paid Parent Provider Program 
• Arizona DES/DDD Division Operations Policy 3001 Family Members As Paid Providers
• Arizona DES/DDD September 4, 2025 Public Forum Presentation Related To Planning Meeting & Assessment Changes Including Parents As Paid Caregivers
• Enrolled CS/CS/HB 1103 (2025) – Services For Individuals With Developmental Disabilities
• Colorado HCPF Proposed Individual Residential Services & Supports (IRSS): Rate Alignment Fact Sheet
• A Strategic Path To Affiliations: The Advocates Case Study

See All

HHS Announces Actions To Address Rising Autism Prevalence

At a September 22 press event, President Donald J. Trump and U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. announced actions to address what an accompanying press release described as an “autism spectrum disorder (ASD) epidemic.” Actions include a U.S. Food and Drug Administration (FDA) label update for leucovorin for cerebral folate deficiency, authorizing treatment for children with ASD and enabling state Medicaid programs to cover leucovorin for the indication… Read

• New York To Award Up To $25 Million In Funding For New Regional Disability Health Clinics
• Governor Hochul Announces $25 Million To Expand Access To Health Care For People With Developmental Disabilities
• Retention Is The New Recruitment
• Caravel Autism Health Opens Therapy Clinic Designed For Children In St. Cloud, Minnesota
• STEPS Behavioral Health Opens Third Autism Care Clinic In Maryland

To sign-up for monthly Autism & I/DD Services alerts, you must be signed in to your account.